188 related articles for article (PubMed ID: 18922176)
41. Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer.
Offersen BV; Riisbro R; Knoop A; Brünner N; Overgaard J;
Acta Oncol; 2007; 46(6):782-91. PubMed ID: 17653901
[TBL] [Abstract][Full Text] [Related]
42. Progestin inhibits and thrombin stimulates the plasminogen activator/inhibitor system in term decidual stromal cells: implications for parturition.
Norwitz ER; Snegovskikh V; Schatz F; Foyouzi N; Rahman M; Buchwalder L; Lee HJ; Funai EF; Buhimschi CS; Buhimschi IA; Lockwood CJ
Am J Obstet Gynecol; 2007 Apr; 196(4):382.e1-8. PubMed ID: 17403427
[TBL] [Abstract][Full Text] [Related]
43. High concentrations of plasminogen activator inhibitor-1 in lungs of preterm infants with respiratory distress syndrome.
Cederqvist K; Sirén V; Petäjä J; Vaheri A; Haglund C; Andersson S
Pediatrics; 2006 Apr; 117(4):1226-34. PubMed ID: 16585319
[TBL] [Abstract][Full Text] [Related]
44. Protein expression of MMP-13, uPA, and PAI-1 in pseudocapsular and interface tissue around implants of loose artificial hip joints and in osteoarthritis.
Diehl P; Hantke B; Hennig M; Tschesche H; Mittelmeier W; Schmitt M; Muehlenweg B
Int J Mol Med; 2004 May; 13(5):711-5. PubMed ID: 15067375
[TBL] [Abstract][Full Text] [Related]
45. Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer.
Singer CF; Filipits M; Jahn SW; Abete L; Jakesz R; Greil R; Bauernhofer T; Kwasny W; Seifert M; Fitzal F; Kastner M; Schmitt M; Moinfar F; Gnant M
Breast; 2019 Aug; 46():101-107. PubMed ID: 31132475
[TBL] [Abstract][Full Text] [Related]
46. Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer.
Linderholm BK; Gruvberger-Saal S; Fernö M; Bendahl PO; Malmström P
Breast; 2008 Oct; 17(5):484-91. PubMed ID: 18508268
[TBL] [Abstract][Full Text] [Related]
47. Proteins and carbohydrates in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy.
Qin W; Gui G; Zhang K; Twelves D; Kliethermes B; Sauter ER
BMC Cancer; 2012 Feb; 12():52. PubMed ID: 22296682
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
49. Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2.
Mannello F; Qin W; Zhu W; Fabbri L; Tonti GA; Sauter ER
Breast Cancer Res Treat; 2008 Sep; 111(2):209-18. PubMed ID: 17932742
[TBL] [Abstract][Full Text] [Related]
50. A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment.
Herrera FG; Chan P; Doll C; Milosevic M; Oza A; Syed A; Pintilie M; Levin W; Manchul L; Fyles A
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):97-103. PubMed ID: 17056201
[TBL] [Abstract][Full Text] [Related]
51. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.
Janz M; Harbeck N; Dettmar P; Berger U; Schmidt A; Jürchott K; Schmitt M; Royer HD
Int J Cancer; 2002 Jan; 97(3):278-82. PubMed ID: 11774277
[TBL] [Abstract][Full Text] [Related]
52. Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinoma.
Dorn J; Harbeck N; Kates R; Magdolen V; Grass L; Soosaipillai A; Schmalfeldt B; Diamandis EP; Schmitt M
Biol Chem; 2006 Aug; 387(8):1121-8. PubMed ID: 16895483
[TBL] [Abstract][Full Text] [Related]
53. Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer.
Kolben T; Augustin D; Armbrust R; Kolben TM; Degenhardt T; Burgmann M; Goess C; Ditsch N; Kates R; Harbeck N; Wuerstlein R
Breast Cancer Res Treat; 2016 Jan; 155(1):109-15. PubMed ID: 26643086
[TBL] [Abstract][Full Text] [Related]
54. Neoadjuvant therapy with celecoxib to women with early stage breast cancer.
Tfayli A; Yang J; Kojouri K; Kesserwan C; Jafari M; Ozer H
Neoplasma; 2008; 55(2):122-6. PubMed ID: 18237249
[TBL] [Abstract][Full Text] [Related]
55. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
56. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer.
Palmirotta R; Ferroni P; Savonarola A; Martini F; Ciatti F; Laudisi A; Sini V; Del Monte G; Guadagni F; Roselli M
Thromb Res; 2009 Sep; 124(4):403-8. PubMed ID: 19351570
[TBL] [Abstract][Full Text] [Related]
58. The reliability of nipple aspirate and ductal lavage in women at increased risk for breast cancer--a potential tool for breast cancer risk assessment and biomarker evaluation.
Visvanathan K; Santor D; Ali SZ; Brewster A; Arnold A; Armstrong DK; Davidson NE; Helzlsouer KJ
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):950-5. PubMed ID: 17507621
[TBL] [Abstract][Full Text] [Related]
59. JNK suppression is essential for 17β-Estradiol inhibits prostaglandin E2-Induced uPA and MMP-9 expressions and cell migration in human LoVo colon cancer cells.
Hsu HH; Hu WS; Lin YM; Kuo WW; Chen LM; Chen WK; Hwang JM; Tsai FJ; Liu CJ; Huang CY
J Biomed Sci; 2011 Aug; 18(1):61. PubMed ID: 21859479
[TBL] [Abstract][Full Text] [Related]
60. Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients.
Pedersen AN; Brünner N; Høyer-Hansen G; Hamer P; Jarosz D; Larsen B; Nielsen HJ; Stephens RW
Clin Chem; 1999 Aug; 45(8 Pt 1):1206-13. PubMed ID: 10430786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
